Metformin induces apoptosis and downregulates pyruvate kinase M2 in breast cancer cells only when grown in nutrient-poor conditions

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Silvestri, Alessandra ^a,c   Palumbo, Francesco ^a   Rasi, Ignazio ^a   Posca, Daniela ^a,d   Pavlidou, Theodora ^a   Paoluzi, Serena ^a   Castagnoli, Luisa ^a   Cesareni, Giovanni ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c Cpo Cellular Phenomics and Oncology GmbH   (Germany)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PROTEIN KINASE B; PYRUVATE KINASE; PYRUVATE KINASE M2; RAPAMYCIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CULTURE MEDIUM; PHARMACEUTICAL VEHICLES AND ADDITIVES;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; GLYCOLYSIS; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CULTURE MEDIUM; DRUG EFFECTS; ENZYMOLOGY; FEMALE; MCF-7 CELL LINE; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADJUVANTS, PHARMACEUTIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CULTURE MEDIA; DOWN-REGULATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MCF-7 CELLS; METFORMIN; PYRUVATE KINASE; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84943189015     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136250     Document Type: Article

References (43)

1. Adler AI, Shaw EJ, Stokes T, Ruiz F, Guideline Development Group. Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance. BMJ. 2009; 338: b1668. doi: 10.1136/bmj.b1668 PMID: 19465464
2. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203. doi: 10.2337/dc08-9025 PMID: 18945920
3. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393-403. PMID: 11832527
4. Bailey CJ. Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther. 2008; 22: 215-224. doi: 10.1007/s10557-008-6092-0 PMID: 18288595
5. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and metaanalysis. BMJ. 2003; 327: 951-953. PMID: 14576245
6. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012; 48: R31-43. doi: 10.1530/JME-12-0007 PMID: 22355097
7. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330: 1304-1305. PMID: 15849206
8. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010; 3: 1451-1461.
9. Meiers P, Sharon E, Dong Yu W, Pooni A, McCready D, Leong W. Significant reduction of triple negative breast cancers in diabetic women on metformin. San Antonio Breast cancer Symposium. 2010; 70 (24 Suppl.): Abstract nr PD03-01.
10. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes. 2004; 53: 1052-1059. PMID: 15047621
11. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000; 275: 223-228. PMID: 10617608
12. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005; 1: 15-25. PMID: 16054041
13. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003; 17: 1829-1834. PMID: 12869586
14. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009; 8: 909-915. PMID: 19221498
15. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009; 8: 2031-2040. PMID: 19440038
16. Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat. 2010; 123: 271-279. doi: 10.1007/s10549-010-0763-9 PMID: 20135346
17. Zhuang Y, Miskimins WK. Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol Cancer Res. 2011; 9: 603-615. doi: 10.1158/1541-7786.MCR-10-0343 PMID: 21422199
18. Menendez JA, Oliveras-Ferraros C, Cufi S, Corominas-Faja B, Joven J, Martin-Castillo B, et al. Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle. 2012; 11: 2782-2792. doi: 10.4161/cc.20948 PMID: 22809961
19. Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng XS, Arnadottir SS, et al. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle. 2013; 12: 3759-3769. doi: 10.4161/cc.26641 PMID: 24107633
20. Zordoky BN, Bark D, Soltys CL, Sung MM, Dyck JR. The anti-proliferative effect of metformin in triplenegative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention. Biochim Biophys Acta. 2014; 1840: 1943-1957. doi: 10.1016/j.bbagen.2014.01.023 PMID: 24462945
21. Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell. 2008; 14: 458-470. doi: 10.1016/j.ccr.2008.11.003 PMID: 19061837
22. Berstein LM, Boyarkina MP, Tsyrlina EV, Turkevich EA, Semiglazov VF. More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. Med Oncol. 2011; 28: 1260-1263. doi: 10.1007/s12032-010-9572-6 PMID: 20490716
23. Cossor FI, Adams-Campbell LL, Chlebowski RT, Gunter MJ, Johnson K, Martell RE, et al. Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. Cancer Epidemiol. 2013; 37: 742-749. doi: 10.1016/j.canep.2013.04.015 PMID: 23773299
24. Kalinsky K, Crew KD, Refice S, Xiao T, Wang A, Feldman SM, et al. Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest. 2014; 32: 150-157. doi: 10.3109/07357907.2014.889706 PMID: 24605899
25. Hwang YP, Jeong HG. Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1. Br J Pharmacol. 2010; 160: 1195-1211. doi: 10.1111/j.1476-5381.2010.00762.x PMID: 20590612
26. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007; 67: 10804-10812. PMID: 18006825
27. Malki A, Youssef A. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol Res. 2011; 19: 275-285. PMID: 21776823
28. Zakikhani M, Bazile M, Hashemi S, Javeshghani S, Avizonis D, St Pierre J, et al. Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin. PLoS One. 2012; 7: e49513. doi: 10.1371/journal.pone.0049513 PMID: 23185347
29. Zhuang Y, Chan DK, Haugrud AB, Miskimins WK. Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo. PLoS One. 2014; 9: e108444. doi: 10.1371/journal.pone.0108444 PMID: 25254953
30. Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012; 11: 367-376. doi: 10.4161/cc.11.2.18813 PMID: 22189713
31. Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell. 2012; 45: 598-609. doi: 10.1016/j.molcel.2012.01.001 PMID: 22306293
32. Blandino G, Valerio M, Cioce M, Mori F, Casadei L, Pulito C, et al. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun. 2012; 3: 865. doi: 10.1038/ncomms1859 PMID: 22643892
33. Reinacher M, Eigenbrodt E. Immunohistological demonstration of the same type of pyruvate kinase isoenzyme (M2-Pk) in tumors of chicken and rat. Virchows Arch B Cell Pathol Incl Mol Pathol. 1981; 37: 79-88. PMID: 6116351
34. Brinck U, Eigenbrodt E, Oehmke M, Mazurek S, Fischer G. L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Arch. 1994; 424: 177-185. PMID: 8180780
35. Steinberg P, Klingelhoffer A, Schafer A, Wust G, Weisse G, Oesch F, et al. Expression of pyruvate kinase M2 in preneoplastic hepatic foci of N-nitrosomorpholine-treated rats. Virchows Arch. 1999; 434: 213-220. PMID: 10190300
36. Gupta V, Bamezai RN. Human pyruvate kinase M2: a multifunctional protein. Protein Sci. 2010; 19: 2031-2044. doi: 10.1002/pro.505 PMID: 20857498
37. Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell. 2013; 155: 397-409. doi: 10.1016/j.cell.2013.09.025 PMID: 24120138
38. Goldberg MS, Sharp PA. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med. 2012; 209: 217-224. doi: 10.1084/jem.20111487 PMID: 22271574
39. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther. 2011; 10: 2350-2362. doi: 10.1158/1535-7163.MCT-11-0497 PMID: 21992792
40. Marini C, Salani B, Massollo M, Amaro A, Esposito AI, Orengo AM, et al. Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle. 2013; 12: 3490-3499. doi: 10.4161/cc.26461 PMID: 24240433
41. Janzer A, German NJ, Gonzalez-Herrera KN, Asara JM, Haigis MC, Struhl K. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci U S A. 2014; 111: 10574-10579. doi: 10.1073/pnas.1409844111 PMID: 25002509
42. Chen G, Feng W, Zhang S, Bian K, Yang Y, Fang C, et al. Metformin inhibits gastric cancer via the inhibition of HIF1alpha/PKM2 signaling. Am J Cancer Res. 2015; 5: 1423-1434. PMID: 26101707
43. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012; 122: 253-270.